Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

Lineage Cell Therapeutics Provides Update on ReSonance Program Advancement | WAPE

Back All news

Newsfiscal.ai

Lineage Cell Therapeutics Provides Update on ReSonance Program Advancement

Oct 30, 2026, 09:03 ET · Published

View source

Article summary

Lineage Cell Therapeutics announced that its Joint Scientific Committee has approved the advancement of the ReSonance (ANP1) hearing loss program into the second year of its research collaboration with William Demant Invest A/S.

An excerpt from the original article.

Related companies

Lineage Cell Therapeutics, Inc. Common StockLCTXView stock

Lineage Cell Therapeutics Provides Update on ReSonance Program Advancement

Article summary

Related companies

Analyzed by WAPE AI.

Comments —